Risk Factors Update Summary

• Identified substantial doubt about ability to continue as a going concern due to insufficient cash.
• Potential fines under GDPR increased to up to 20 million Euros or 4% of total worldwide annual turnover.
• Addition of "one or more" collaborations increases reliance on third parties for development and commercialization.
• A 1-for-20 reverse stock split was effected on September 28, 2023, potentially affecting trading liquidity.
• Net loss decreased from $56 million to $47 million for the year ended December 31, 2023.
• Mention of ongoing litigation challenging FDA approvals impacting the development and commercialization of products.
• President Biden signed an executive order implementing the EU-U.S. Data Privacy Framework.
• Switzerland is in the process of approving an adequacy decision for data transfers to the U.S.
• Accumulated deficit increased from $1.1 billion to $1.2 billion as of December 31, 2023.
• Mention of "manufacturing delays" if third-party contractors prioritize other products over emavusertib.
• Addition of potential delays in commencing clinical studies in the EU due to new regulations.
• The EC adopted an adequacy decision on July 10, 2023, permitting U.S. companies to rely on the EU-U.S. Data Privacy Framework.
• Privacy and data security laws in various countries may impact business activities and increase compliance costs.
• Sales of Erivedge were first recorded in the U.S. during the fourth quarter of 2015.
• Inclusion of "manufacturing delays" due to potential interruptions in the supply of raw materials.
• Inclusion of risks associated with the delay in obtaining marketing approval in foreign jurisdictions.
• Entered into a new sales agreement allowing the sale of up to $100.0 million of common stock.
• Introduction of risks related to Brexit and the need for new marketing authorizations in the UK.
• The UK and the EU have determined data transfers between them are compliant with the UK Data Protection Act and GDPR.
• Estimated amount of the Put/Call Price decreased from $72.5 million to $56.9 million as of December 31, 2023.
• Deprioritized and did not exercise the option to license CI-8993 after not reaching the maximum tolerated dose.